We scan new podcasts and send you the top 5 insights daily.
Bill Williams says BriaCell's phase 3 seeks a 40% reduction in mortality. If it misses that, the company can continue and aim for a 30% reduction; FDA agreed either result would support full approval for the therapy, so no separate confirmatory study would be needed.
Instead of stopping a trial early for success—which regulators may restrict—a high-confidence early signal provides immense value as business intelligence. This allows sponsors to de-risk and accelerate planning for subsequent phases months earlier, creating millions in value by reducing the gap between Phase 2 and 3.
Despite a marginal miss on a key secondary endpoint (microperimetry), Beacon's gene therapy is on a clear path to FDA approval. The company "absolutely smashed" the pre-agreed primary endpoint, demonstrating that a strong, regulator-aligned primary outcome is the most critical factor for a straightforward approval process.
Bill Williams says HLA matching was not as critical for Bria-IMT when combined with an immune checkpoint inhibitor, so BriaCell is not matching patients for that product. The company is instead building HLA matching into its next-generation Bria-OTS and OTS Plus pipelines as those programs advance.
Cereno Scientific chose a Phase 2b trial over a combined 2b/3 to maintain flexibility. A combined trial locks in the design for both phases upfront, whereas a standalone 2b allows for optimization before Phase 3 and creates a cleaner, more attractive asset for a potential acquisition deal.
While the FDA avoids providing an explicit number, analysis of previously approved drugs in this indication reveals a clear benchmark. A complete response (CR) rate of "about two-thirds" in the pivotal trial is the unofficial target companies like enGene must hit to be considered in the approvable range.
An expert speculates that the durable responses and plateauing four-year survival curve from the EV302 trial indicate a potential cure rate of 30% in metastatic bladder cancer, a dramatic improvement over historical outcomes of 5-10%.
After two FDA rejections for its cell therapy RyanCell, Mesoblast finally secured approval by supplementing its initial data. The company demonstrated impressive five-year survival outcomes and developed assays to prove manufacturing consistency, addressing the FDA's core concerns and showcasing the resilience required for pioneering new therapies.
While depth of response strongly predicts survival for an individual patient, the FDA analysis concludes it cannot yet be used as a surrogate endpoint to replace overall survival in pivotal clinical trials. It serves as a measure of drug activity, similar to response rate, but is not sufficient for drug approval on its own.
To be considered a success, Abivax's oral drug Obifazomad must demonstrate placebo-adjusted long-term remission rates of 25-30% in upcoming data, matching the efficacy of top biologic treatments for ulcerative colitis. Its strong phase two results, showing a 48% rate, suggest this benchmark is achievable, positioning it as a potential "holy grail" oral therapy.
The GLORA-IV trial is designed with a dual endpoint, evaluating both patient response rate and overall survival. This structure creates an alternative pathway for regulatory approval based on response rates, which can be assessed faster than survival, strategically de-risking the lengthy and expensive trial process.